Tags Posts tagged with "Cannabis"

Cannabis

0 1298

Future Farm Closes on 15 Acres of Cannabis Zoned Land in Florida and Appoints John Sweeney as Chief Operating Officer

VANCOUVER, British Columbia, Feb. 8, 2017 /PRNewswire/ — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (OTCQB: AGSTF) (CSE: FFT) is pleased to announce that it has closed on its previously announced definitive agreement to acquire a 15-acre parcel of land in Redland, Florida, in a county that is designated to legally cultivate, process and dispense cannabis. Redland is an unincorporated community within Miami-Dade County, with Biscayne National Park to the east and Everglades National Park to the west. Redland is primarily a Miami suburb and a major agricultural area. Miami-Dade County is referred to as the nation’s “Salad Bowl” and “Winter Bread Basket.”

“We are pleased to have reached this contract to acquire this prime parcel of land as it has a long history as a plant nursery, which was first established in 1963,” says Mr. William Gildea, Future Farm Technologies Inc.’s CEO and Chairman. Florida’s Legislature is beginning the process of figuring out how to implement Amendment 2, which allows for the expansion of legalized medical marijuana in Florida. The new law took effect on Tuesday, Jan. 3, 2017. The Florida Department of Health now has until June 3, 2017 to finalize its MMJ regulations and until September 3, 2017 to issue the first ID cards to patients. Amendment 2 was approved by 71 percent of Florida voters on Election Day, and will allow higher-strength marijuana to be used for a wider list of medical ailments.

With this acquisition, Future Farm has the potential, if fully licensed, to develop 15-acres of cannabis crops and is positioning itself to be a part of the Florida Cannabis market as it rolls out in 2017. If current state projections for the cannabis market size hold up to their $1.8B projection by 2020, Florida will have considerable demand for medical marijuana, even without factoring in the potential for recreational legislation.

This is an exciting acquisition for Future Farm as the 15-acre farm is located in a designated legal grow zone with close proximity to Miami. Future Farm is in a unique position as a Canadian based company because it is poised to quickly commence operations within the United States rather than potentially wait years to become a licensed producer under Canadian law.

Concurrent with this announcement, the Company is pleased to announce the appointment of John Sweeney as its Chief Operating Officer. Mr. Sweeney will transition into this executive position from his current role as a consultant and his big pharma background and expertise will help the Company capitalize on its current growth initiatives.

While serving as a consultant for the Company, Mr. Sweeney helped position the business firmly within the North American cannabis market through organic and inorganic growth initiatives. Going forward, Mr. Sweeney is going to play an important role in the next phase of the Company’s growth strategy.

Mr. Sweeney brings with him 16 years of direct cGMP (current Good Manufacturing Practices) manufacturing experience in operations of industry leading biotechnology companies including Pfizer, Wyeth, Genzyme and most recently as Vice President of Operations at Tilray, a 60,000-square foot federally licensed Canadian medical cannabis operation on Vancouver Island.

He has extensive knowledge and experience in the requirements of regulated manufacturing for commercial and clinical products and served as liaison for auditing regulatory agencies including the FDA and EMA. Mr. Sweeney holds an MS in Engineering Management from Tufts University in Medford, MA and a BS in Biology from the University of New Hampshire, Durham.

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, CEO & Chairman

About Future Farm

The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, contact William Gildea, Director, at 617.834.9467.

2 2272

This morning Reliq Health Technologies (OTC:RQHTF) (TSX VENTURE:RHT) announced that through an MOU with Invictus MD Strategies Corp. (CSE:IMH)(OTC:IVITF) the company would be diving into the marijuana industry through the development of a mobile application for cannabis patients and consumers and their clinical care teams. Another clear example of how “Bio-tech” is beginning to carve its own space within the marijuana industry.

Reliq Health, a healthcare technology company focused on developing innovative mobile health and telemedicine solutions, has developed a novel SaaS (software as a service) solution for the community health care market. The solution provides automated remote patient monitoring in the home and secure cloud-based communication, care planning and collaboration for all members of the patient’s circle of care. Reliq’s secure platform allows clinicians to collect comprehensive data on patients’ clinical conditions, medication usage, symptoms, side effects and behaviours – creating a wealth of population health data.

“Studies consistently show that providing patients with the tools they need for self-management of their health conditions produces better health outcomes and reduces healthcare costs. Cannabis is prescribed to treat a wide range of conditions including arthritis, glaucoma, side effects from chemotherapy, chronic pain, multiple sclerosis and post-traumatic stress disorder.

Our cannabis app allows patients to track usage and record symptoms specific to their clinical condition, allowing patients and their care providers to determine optimum strain, dosing and mode of administration. Our platform will improve access to care by connecting patients with physicians in their community who have experience with medical marijuana, and supports physician-approved automated prescription refills through participating producers,” said Dr. Lisa Crossley, CEO of Reliq.

Invictus MD’s Chairman and CEO, Dan Kriznic, said, “Our wholly owned subsidiary: Poda Technologies Ltd. (“Poda“) is set for a launch in Q2 2017 of its Poda Pod vaporizer product which will provide an effective, reliable and convenient way to vaporize cannabis that is designed to appeal to modern retail and medical consumers.” The Poda Pod vaporizer product, made with medical-grade components, has been designed to connect to users’ smartphones via Bluetooth to provide real time information about dosage, product characteristics, track remaining contents, find vendors nearby, and customize their experience. Agreements are being negotiated to license the PODA products to the Access to Cannabis for Medical Purposes Regulations (“ACMPR“) and licensed producers in Canada, helping those producers better reach and serve consumers with convenient, refillable devices.

Mr. Kriznic added, “Invictus MD is excited and committed to working collaboratively with Reliq on this innovative mobile application to explore how Reliq’s solution can support Invictus’ commitment to its patients and consumers of cannabis products. Reliq’s technology platform will give Invictus the ability to collect relevant anonymized consumer data such as usage trends, frequency of usage and other relevant insights to improve the overall experience for medical marijuana patients.”

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company”) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.


Pursuant to an agreement between us and Reliq Health Technologies, Inc. we have been hired for a period of 30 days to publicly disseminate information about (RQHTF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (RQHTF), which we purchased in the open market. We plan to sell the “ZERO” shares of (RQHTF) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (RQHTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2112

mCig, Inc. (MCIG) continued to show strong growth on a quarter-over-quarter basis after the company reported preliminary results for the third quarter which ended on January 31st.

mCig has shown incremental growth following the company’s transition from a pure-play vaporizer company to a diversified holding company focused on the legal cannabis, hemp, and CBD markets as well as the picks & shovels approach with Greenhouse & other cultivation construction projects via their Scalable Solutions division.

Highlights from the company’s third quarter include:

● Generated $1.3 million in revenue (200% higher than the prior quarter) through its construction, CBD, and e-Cig divisions
● Reported $845,000 in net income (adjusted net income of $118,00), a company record
● Generated $341,000 in cash from operations and increased its cash, and cash equivalents to $420,000
● Reported to have more than $1.2 million in current assets with only $287,000 in current liabilities. This provides mCig with an acid test ratio of 4.3:1, its highest rating in company history.

The company’s success in the third quarter has brought total revenue for this fiscal year to $2.2 million. The revenue generated represents a 546% increase from the same period last year, and a 204% increase from last quarter.

MCIG’s net income during the quarter increased its total net income for the fiscal year to $716,000 (32% net profit margin).

From the Management Team

Michael Hawkins, Chief Financial Officer, stated, “For the third straight quarter MCIG has recorded record numbers. With its current contracts and booked revenue the Company will continue to see quarter over quarter growth in revenue.” He went on to say, “During this quarter we will revamp our segment reporting; changing from construction, wholesale, and retail; to construction, CBD, and e-Cig operations. We feel reporting on the segments under these new categories will provide a greater in depth review of our operations to our shareholders and investors.”

mCig CEO Paul Rosenberg said, “The cannabis industry is growing rapidly and MCIG has been there since the beginning. Management continues to focus on its business grow opportunities in Nevada, while continuing to service other states as well.”

A Trend to Watch

Over the last year, mCig has expanded its offering as well as the states it operates out of. The company recently entered its first business agreement in Maine which marked the sixth state the company is operating out of.
Investors should keep an eye on MCIG as this is a company to watch as they continue to expand their cultivation construction arm in the Nevada market, which we anticipate will become the most lucrative market outside of California. The continued execution coupled with a more attractive product and service line has made mCig an attractive partner for many businesses and we expect to see further expansion from here.

We may buy or sell additional shares of (MCIG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER (http://marijuanastocks.com/content/terms-and-conditions-use/)

0 2134

Marijuana Stocks, Inauguration Day, & Trump’s Bump

Here we are, just after the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.


Click Here To View Full Article


 

Facts Regarding Denver’s New Marijuana In Public Law

Denver has begun working on the country’s first law allowing use in public places like coffee shops and cannabis clubs. However, the details about what those marijuana clubs would look like are still unclear. Here are some answers to questions about the cannabis clubs headed to Denver.


Click Here To View Full Article


 

Veterans In Support Of Medical Marijuana



Indiana American Legion reached an agreement on Sunday that would support a medical cannabis study to treat injuries to military service members, such as traumatic brain injuries and PTSD. The veteran service organization said they are working to urge Indiana legislators to approve the private growth and research of medicinal cannabis and to reclassify marijuana as a drug with potential medical value.


Click Here To View Article


 

 

 PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 11440

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

Medical Marijuana Shows Parkinson’s Patient Some Relief

Ian Frizell, age 55, was diagnosed with Parkinson’ disease in 2011. He has suffered from symptoms since 1995, which continually got worse over time. Ian has filmed a video to display what a significant difference a small amount of medical marijuana makes to his tremors. In the clip, he states that he recently underwent deep brain stimulation surgery, a medical implant that helps hide the effects of Parkinson’s. He switches the DBS device off to show the seriousness of his tremors.

 


Click Here To View Full Article


 

Research Reveals Some Of Marijuana’s Health Effects

 

It may essentially help some people sleep and ease chronic pain, but it is also possible to heighten the danger of triggering a heart attack or develop schizophrenia. A Federal advisory panel came to those those conclusions about cannabis in a recent report.

The analysts also called for a…


Click Here To View Full Article


 

Vitality Biopharma (VBIO)

 

Vitality Biopharma (VBIO) has been in our spotlight for the better part of the last few weeks and we’ve seen this cannabis biotech deliver real potential for gains. What started out as a $0.98 alert ended up turning into a $4.24 bull. Even after pulling into $1.93, VBIO managed several clear bounces. This will be something we’ll be continuing to monitor into the later half of the month as well. If you haven’t taken a look at this company yet, check out our full report via the link below.


Click Here To View Full VBIO Report


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1226

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA–(Marketwired – Jan 9, 2017) – Vitality Biopharma, Inc. ( OTCQB : VBIO ) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA

Investors and other interested parties will be able to access a copy of the presentation by visiting the investors section of the Vitality Biopharma website at http://vitality.bio/investors/presentation.

About Biotech Showcase 2017
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

About Vitality Biopharma ( OTCQB : VBIO )
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 687

 Vitality Biopharma (VBIO) Set To Continue Trend Into “BigWeek” For Biotech?

 

Today’s the day that kicks off JPMorgan’s annual health-care conference; coined the industry’s biggest gathering. As we said last week, many in the space have said that this conference has proven to be a catalyst for the sector overall. So why mention this, as a marijuana focused outlet? Our most recent featured company Vitality Biopharma (VBIO) finds itself at the cross-roads where cannabis meets biotech. Not only did VBIO see a green close on Friday after 3 consecutive days of consolidation but it’s also heading into the week where biotech will seemingly be in the spotlight for many investors.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.


Click Here To View Full VBIO Report


 

Dive Into The Steady Growing Cannabis Market

 

Co-founder of Vapium, a Canadian marijuana vape-maker states, “If you have a passion, any passion, we need advocates and allies. If you’re a baker, we need bakers. If you’re a lawyer, we need lawyers. Anyone who has empathy for people who need weed, and is driven, is welcome in the marijuana industry. There’s still so much opportunity.” The cannabis industry seems like it’s ready to take off. In 2016, the legal weed market in North America Generated $6.7 billion, up 30% from 2015, Arcview Market Research announced.

Washington DC has passed laws allowing…


Click Here To View Full Article


 

Lets Take a Deeper Look at California’s Most Popular Crop

 

California was already known as a major cannabis producer well before it legalized recreational marijuana in November. The state’s marijuana crop is not only the most profitable product in the nation’s biggest agricultural state, it is much farther ahead of the next most popular crop, according to the Orange County Register. California’s mild climate made Central Valley the breadbasket of the world at one time and provided the United States with fruits and vegetables that grew in very few other places. However, the biggest crop in California’s assorted bounty is currently marijuana.


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2268

 

What To Watch With Vitality Biopharma ($VBIO)

 

Vitality Biopharma (VBIO) is staying at the top of our list this week. We’ve witnessed first-hand how strong of a run that this has had and continues to have. Over the last few days we’ve seen VBIO hold a tend above $2.50, where last week it saw a trend in the higher $1 range. In fact since last week, VBIO is trending more than 30% higher than those previous lows. Keep in mind that within the last few weeks VBIO has hit highs of $4.23 so as many of you have already witnessed, this has been capable of dynamic breakouts over shorter periods of time.

This is all happening as the company continues to make progress with their novel therapies. has been going by route of prodrugs. Their unique approach targets CB2 receptors and can be taken orally to directly target specific tissues or organs. Right now, the company is working to create therapies for Crohn’s disease patients and those who suffer from inflammatory bowel disease. VBIO has filed intellectual property applications and is seeking worldwide patent protection through 2035, with strong composition of matter claims for its prodrugs.

In fact, the company’s novel use of certain developmental therapies have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. And if you remember, they’ve also just received the Drug Enforcement Administration’s approval for its pharma development facility…something that not many of its competitors (if any) can say right now especially in the current climate. Looking for more on VBIO?

 


Click Here To View Full VBIO Report



Things To Expect After Medical Cannabis Is Legal In Florida

Dr. Joseph Dorn was the medical director of Surterra Therapeutics, which is one of six distributing locations that are licensed to dispense medical marijuana in the state of Florida. The constitutional amendment allows higher-strength cannabis to be used for a broader range of medical conditions. However, the true measure of what the amendment means won’t be seen immediately until a new set of rules are carried out by the State’s Legislature.


Click Here To View Full Article


 

#ICYMI: Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

 

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.

 


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 698

 

Vitality Biopharma ($VBIO)’s 3-Day Rally Set To Continue?

Vitality Biopharma (VBIO) saw a very strong run during most of December. When we first began to pick up coverage it was sitting around $0.98 and during the course of the weeks to follow, we watched as VBIO ran to highs of $4.23. Despite the fact that many thought the excitement was over when VBIO pulled back, we’ve now seen it breakout once again. In fact since bottoming at $1.93 last week, VBIO has maintained a 3 day run that has taken it back to highs of $3.22 yesterday; a 67% rebound.

We said it late last year and the sentiment continues to hold up so far in 2017: Canna-biotech companies have begun to catch much more attention; biotech over all has begun to see an increase in activity following President Elect Trump coming into the spotlight. In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%. This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were recetnly reviewed and approved by the U.S. FDA. So, if is your first time seeing VBIO, we’ve got a full report you can access before the opening bell today.

 


Click Here To View Full VBIO Report



The Hero of HOLLYWEED

 

In case you missed it this New Years the citizens and tourists got a wonderful welcome when they looked up at Mount Lee in HollyWood, or should we say “HOLLYWEED!” The Iconic Hollywood sign was given a hilarious, yet impactful redesign given that the state of California now has recreational marijuana after a November 8th vote in favor of the law change by its illustrious citizens.

 


Click Here To View Full Article


 

Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.


Click Here To View Full Article



Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements